[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593133":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":42,"responsibleParty":58,"collaborators":26,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":26,"enrollmentInfo":70,"targetDuration":26,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":45,"whyStopped":26,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Shanghai East Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Group","ACTIVE_COMPARATOR","Guideline-recommended standard of care",[13],"Drug: guideline-recommended SoC",{"label":15,"type":16,"description":17,"interventionNames":18},"Investigational Group","EXPERIMENTAL","Guideline-recommended standard of care+intensive lipid-lowering therapy",[19],"Drug: Recaticimab (intensive)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","guideline-recommended SoC","Guideline-recommended SoC, including but not limited to oral lipid-lowering drugs, antiplatelet aggregation drugs, anticoagulant drugs, antihypertensive drugs, etc. It is to be determined by the investigator based on the subject's treatment needs.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Recaticimab (intensive)","Recaticimab is added to the guideline-recommended SoC. After randomization and before endovascular interventional treatment, patients will receive a subcutaneous injection of Recaticimab. The specific method is: Recaticimab 450 mg (3 vials) as a single subcutaneous injection, until the end of the follow-up for this study.",[15],[32],{"name":5,"affiliation":33,"role":34},"Tongji University","STUDY_CHAIR",[36],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},"Gang Li, MD","CONTACT","86021-38804518","22107","ligang@tongji.edu.cn",[43],{"facility":44,"status":45,"city":46,"state":26,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Shanghai East Hospital, Tongji University","RECRUITING","Shanghai","200127","China","CN",{"type":51,"coordinates":52},"Point",[53,54],121.45806,31.22222,{"lat":54,"lon":53},[57],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},{"type":59,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100593133","phase-3-early-aggressive-strategy-for-treatment-of-lipid-lowering-in-acute-ischemic-stroke-delivered-with-endovascular-therapy-for-large-artery-occlusion-100593133",false,"NCT07002476","Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion","A Prospective, Multicenter, Open-Label, Randomized Controlled Study of Early Intensive Lipid-Lowering in Endovascular Treatment for Acute Ischemic Stroke","EAST-LDL","Inclusion Criteria:\n\n* Adults (age 18 years and older);\n* Imaging diagnosis of acute ischemic stroke with anterior circulation large vessel occlusion (including: internal carotid artery, middle cerebral artery M1 and M2, anterior cerebral artery A1 and A2);\n* Planned to undergo endovascular intervention within 24 hours of symptom onset (or last known well time) according to local guidelines;\n* Provision of informed consent by the patient or his\u002Fher legally authorized representative (or by an appropriate agent according to local requirements).\n\nExclusion Criteria:\n\n* ASPECTS score ≤5 on cranial CT imaging;\n* Pre-existing functional impairment, with mRS score \\>2;\n* Patients who are allergic to PCSK9 inhibitors;\n* Patients who have received PCSK9 monoclonal antibody within 1 month prior to enrollment or PCSK9 siRNA therapy within 6 months prior to enrollment;\n* Severe renal insufficiency, defined as estimated glomerular filtration rate (eGFR) \\\u003C 15 mL\u002Fmin\u002F1.73m2 at final screening;\n* Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 3 times the upper limit of normal;\n* Severe, concomitant non-cardiovascular disease expected to reduce life expectancy to less than 3 months;\n* Pregnant or lactating women;\n* Patients who are participating in other clinical trials;\n* Other conditions deemed unsuitable for inclusion in the clinical study by the investigator.","ALL","18 Years",{"count":71,"type":72},652,"ESTIMATED","INTERVENTIONAL",[75],"PHASE3","A prospective, multicenter, open-label, randomized controlled study to assess the effects of early intensive lipid-lowering initiated before endovascular treatment setting on (i) functional outcome in patients with acute ischemic stroke between preoperative intensive lipid-lowering therapy with PCSK9 inhibitor (PCSK9i) and guideline-recommended standard of care (SoC)(ii) safety in these patients.",[78],"Stroke",[80,81,82,83,84],"acute ischemic stroke","LDL-Cholersterol lowering","Endovascular Therapy","PCSK9","clinical trials","2026-01-18",{"date":87,"type":88},"2026-01-21","ACTUAL",{"date":90,"type":88},"2025-06-19",{"date":92,"type":72},"2029-01-01",{"name":5,"class":6},1]